Form 4: Prelude Therapeutics Grants Options to CFO Lim

Prelude Therapeutics Inc. granted its Chief Legal Officer, Chief Financial Officer, and Corporate Secretary, Bryant David Lim, 275,000 employee stock options with an exercise price of $2.30.

Summary

• Bryant David Lim, the Chief Legal Officer, Chief Financial Officer, and Corporate Secretary of Prelude Therapeutics Inc. (PRLD), was granted 275,000 employee stock options.
• The transaction date for this grant was February 4, 2026.
• Each option has an exercise price of $2.30.
• The options will vest as to 25% of the total shares on February 4, 2027, and thereafter vest as to 1/48 of the total shares monthly until fully vested.
• The vesting is contingent upon Mr. Lim's continued provision of service to the Issuer on each vesting date.
• The expiration date for these options is February 3, 2036.
• Following this transaction, Mr. Lim beneficially owns 275,000 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the grant of stock options to a key executive fosters alignment between management and shareholder interests, incentivizing long-term company performance.

Positives

• The grant of 275,000 employee stock options to a key executive like the CFO/CLO aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The options were granted at a price of $0.00, indicating they are part of a compensation package designed to reward future performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to executive officers is a standard practice across various industries, particularly in biotechnology and pharmaceutical sectors like Prelude Therapeutics. This compensation structure is widely used to attract, retain, and motivate key personnel by linking their personal financial success to the company's long-term stock performance.

Comparison to Industry Standards

• Executive compensation packages, including stock option grants, are common across the biotechnology industry. Companies such as Moderna, BioNTech, and Regeneron frequently utilize similar equity-based incentives to align executive interests with shareholder value.
• The vesting schedule, with an initial 25% after one year and monthly vesting thereafter, is a typical structure designed to encourage long-term commitment and performance, comparable to practices observed at peer companies.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can align management's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees (specifically Bryant David Lim): This grant serves as a significant component of executive compensation, providing a direct financial incentive tied to the company's stock price appreciation.

Next Steps

• Continued service by Bryant David Lim to the Issuer for the options to vest according to the schedule.
• Vesting of 25% of the options on February 4, 2027.
• Subsequent monthly vesting of 1/48 of the total shares until fully vested.

Key Dates

Keywords

Prelude Therapeutics, PRLD, stock options, executive compensation, insider transaction, Form 4, Bryant David Lim